Home  /  Resource Library  /  Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia

Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia

Results of a phase II study examining vemurafenib combined with rituximab for treatment of relapsed hairy cell leukemia. (Abstract only)